Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Wednesday released new metabolite analysis data for ART26.12, a developing analgesic.
ART26.12 is a novel, peripherally acting, non-opioid, non-steroidal analgesic that acts as a fatty acid binding protein 5 (FABP5) inhibitor. The drug was developed for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). A single ascending dose (SAD) study was conducted for ART26.12, with healthy participants receiving a single oral dose of 900 mg. An analysis of the participants' plasma showed only three metabolites, with total metabolite exposure representing 7% of overall drug-related exposure, indicating that the vast majority of circulating drug-related material was ART26.12. The primary metabolite detected accounted for 5% of the total drug exposure and showed the biological activity of ART26.12.
The company reported that the findings suggest a low-risk metabolite profile and suggest that future development of ART26.12 for the treatment of pain is feasible.
ARTL is currently trading at $1.30, down 2.26%.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.